Prexton Therapeutics

Prexton Therapeutics SA (Geneva, Switzerland) develops innovative drugs to improve the quality of life of people who suffer from Parkinson’s disease and other brain disorders. Prexton Therapeutics has the expertise to design novel mGluR4 compounds as new treatment for Parkinson’s disease.
Andreas Segerros, MBA, MSc


Mobile: +45 53 50 30 38
Email Click here to contact